Device Investors Buoyed By Secondhand Optimism
This article was originally published in Start Up
Venture capitalists still might find medical devices to be among the more difficult sectors to place their money, but the overall mood of device investors is improving. Device VCs are encouraged by increasing opportunities on Wall Street along with interest from corporate investors, but limited partners and the FDA remain primary concerns.
You may also be interested in...
Medtech start-ups have closed on some impressive venture capital funding rounds so far this year, with the largest investments concentrated in a few “hot” technology areas. But the biotechnology industry garnered far more VC funding in Q2 than did the medical device sector, particularly with regards to early-stage funding.
In START-UP’s third annual life science venture capital survey, we sent respondents down various tracks depending upon their strategic focus (biopharma vs. device), their employer (traditional venture firm vs. corporate venture group), and other variations. Here are the questions and the complete survey responses.
In our third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare disease are top investment targets.